IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by Haverford Trust Co

Haverford Trust Co increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 16.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 545 shares of the company’s stock after purchasing an additional 77 shares during the quarter. Haverford Trust Co’s holdings in IDEXX Laboratories were worth $275,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Chicago Partners Investment Group LLC boosted its holdings in shares of IDEXX Laboratories by 16.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company’s stock valued at $340,000 after buying an additional 96 shares in the last quarter. Manning & Napier Advisors LLC purchased a new position in shares of IDEXX Laboratories during the second quarter worth about $20,418,000. Oppenheimer Asset Management Inc. increased its position in shares of IDEXX Laboratories by 13.8% during the second quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company’s stock worth $5,825,000 after purchasing an additional 1,453 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of IDEXX Laboratories by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 8,476,054 shares of the company’s stock valued at $4,576,476,000 after purchasing an additional 98,387 shares during the last quarter. Finally, National Pension Service boosted its position in shares of IDEXX Laboratories by 7.3% in the 3rd quarter. National Pension Service now owns 185,972 shares of the company’s stock valued at $93,957,000 after purchasing an additional 12,647 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Down 1.4 %

IDXX opened at $423.65 on Friday. The business has a 50 day simple moving average of $470.26 and a 200-day simple moving average of $483.80. IDEXX Laboratories, Inc. has a 12 month low of $404.74 and a 12 month high of $583.39. The stock has a market capitalization of $34.69 billion, a P/E ratio of 41.45, a P/E/G ratio of 3.72 and a beta of 1.36. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. During the same period in the previous year, the firm earned $2.53 EPS. The business’s revenue was up 6.6% on a year-over-year basis. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the company. BTIG Research started coverage on IDEXX Laboratories in a research report on Thursday, July 25th. They set a “buy” rating and a $580.00 price target on the stock. Piper Sandler reiterated a “neutral” rating and set a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Barclays dropped their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research note on Thursday, October 10th. Finally, JPMorgan Chase & Co. dropped their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average price target of $552.38.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.